Business
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately. James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company. “We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma. “His breadth of biotech and investment experience, coupled with his passion for innovative and transformative life science companies will provide our Board with a unique perspective. We look forward to leveraging his deep industry insights as we continue to advance our robust pipeline of best-in-class potential therapies.” “I am pleased to join Connect Biopharma’s Board of Directors at this exciting time for the company following the two positive readouts for rademikibart in atopic dermatitis and asthma,” commented James Huang, M.B.A. “I look forward to working with my fellow board members and Connect Biopharma’s leadership to advance rademikibart’s development and the broader pipeline of highly differentiated therapeutic candidates.” Mr. Huang has over 30 years of biotech experience and is the Founder and Managing Partner of Panacea Ventures. Prior to Panacea, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where he focused on the firm’s life sciences practice, and a managing partner at Vivo Ventures where he led numerous investments in China. He was also the president of Anesiva, a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior roles in business development, sales, marketing, and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Additionally, Mr. Huang serves as a director on the board...